For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Blog
This week in health care policy: October 16–23, 2026
Medical innovation FDA approves several innovative treatments. Last week, the FDA granted accelerated approval to GSK’s Jemperli for certain untreated…
Search Posts
National Review
RFK Jr.’s Cherry-Picked Science
One of Robert F. Kennedy Jr.’s promises as secretary of health and human services was to bring gold-standard science to our…
Blog
The TrumpRx medicine will prove worse than the disease
On September 30, President Trump, standing alongside the CEO of Pfizer, announced a multifaceted deal wherein Pfizer would inoculate itself from new regulations…
Blog
Free the Economy podcast: Obamacare problems with Jeremy Nighohossian
In this week’s episode we talk about the unintended consequences of the Sarbanes-Oxley Act of 2002, decarbonization of economic growth, and…
Blog
The problem with Obamacare is Obamacare
This year, the COVID-induced expansion of the Affordable Care Act (ACA) will expire. Extending the expanded subsidies has become a point of contention between…
News Release
Report: Pharmaceutical tariffs will upend prices, supply
A new CEI report takes a close look at the complex, worldwide pharmaceutical supply chain to anticipate how forthcoming Trump tariffs might increase prices…
Study
I, Pharmaceutical
The global pharmaceutical industry is complex. This is true not only in the number of countries involved but the range of products, the sets…